文献速递肝病

既存及新发代谢功能障碍增加慢性乙型肝炎患者的肝硬化及其并发症风险

Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B.
PubMed 文献 · Am J Gastroenterol · 2024-06-26

调整临床和病毒因素后,代谢功能障碍组肝硬化风险(aHR 1.82,95%CI 1.40-2.37,P<0.001)和肝硬化并发症风险(每项代谢功能障碍aHR 1.30,95%CI 1.03-1.63,P=0.025)均显著升高,且呈剂量依赖性;随访期间新发糖尿病加重肝硬化并发症风险(aHR 2.87,95%CI 1.34-6.11,P=0.006)。

要点

  • 代谢功能障碍组肝硬化风险显著高于非代谢功能障碍组(aHR 1.82,95%CI 1.40-2.37)。
  • 每增加一项代谢功能障碍,肝硬化并发症风险升高(aHR 1.30,95%CI 1.03-1.63)。
  • 随访中新发糖尿病与肝硬化并发症风险升高相关(aHR 2.87,95%CI 1.34-6.11)。

核心结论

  • 并发及新发代谢功能障碍增加慢性乙型肝炎患者肝硬化和肝硬化并发症风险,且独立于肝脂肪变。
  • 在慢性乙型肝炎患者中主动筛查代谢共病对分层肝病进展风险至关重要。

研究设计与样本

  • 代谢功能障碍依据MASLD定义中的5项心脏代谢标准判定,据此分为代谢功能障碍组(n=7314)与非代谢功能障碍组(n=4188)。

主要发现

  • 代谢功能障碍组患者较非代谢功能障碍组年龄更大、HBV DNA水平更低。
  • 调整临床和病毒因素后,代谢功能障碍组肝硬化风险显著升高(aHR 1.82,95%CI 1.40-2.37,P<0.001)。
  • 代谢功能障碍组肝硬化并发症风险随代谢功能障碍项数呈剂量依赖性升高(每项aHR 1.30,95%CI 1.03-1.63,P=0.025)。
  • 随访期间新发糖尿病加重肝硬化并发症风险(aHR 2.87,95%CI 1.34-6.11,P=0.006)。
  • 肝脂肪变与较低的肝硬化风险(5年内aHR 0.57,95%CI 0.44-0.74,P<0.001)和较低的肝硬化并发症风险(aHR 0.45,95%CI 0.23-0.88,P=0.020)相关;在肝脂肪变患者中,MASLD患者肝硬化风险高于非代谢功能障碍患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing among the chronic hepatitis B (CHB) population. This study aimed to explore the impact of metabolic dysfunction (MD) on cirrhosis and cirrhotic complication risks in CHB. METHODS: Patients with CHB were consecutively recruited between 2006 and 2021. The presence of MD was based on the 5 cardiometabolic criteria specified in the MASLD definition. Patients were categorized into MD/non-MD groups based on these criteria. RESULTS: Eleven thousand five hundred two treatment-naive noncirrhotic patients with CHB were included with a median follow-up of 5.3 years. Patients in the MD group (n = 7,314) were older and had lower hepatitis B virus DNA levels than non-MD patients (n = 4,188). After adjustment for clinical and viral factors, MD patients had significantly higher risks of cirrhosis (adjusted hazard ratio [aHR]: 1.82, 95% confidence interval [CI]: 1.40-2.37, P < 0.001) and cirrhotic complications (aHR: 1.30 per MD, 95% CI: 1.03-1.63, P = 0.025) in a dose-dependent manner. Furthermore, new-onset diabetes mellitus during the follow-up aggravated the risk of cirrhotic complications (aHR: 2.87, 95% CI: 1.34-6.11, P = 0.006). Hepatic steatosis was associated with lower risks of cirrhosis (aHR: 0.57 within 5 years, 95% CI: 0.44-0.74, P < 0.001) and cirrhotic complications (aHR: 0.45, 95% CI 0.23-0.88, P = 0.020). Among individuals with hepatic steatosis, patients with MASLD exhibited a higher cirrhosis risk than non-MD patients. DISCUSSION: Concurrent and new-onset MDs increase the risks of cirrhosis and cirrhotic complications in patients with CHB, independent of hepatic steatosis. Proactively investigating metabolic comorbidities in CHB is critical to stratify the risk of liver disease progression.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Huang SC, Su TH, Tseng TC, et al. Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B. Am J Gastroenterol. 2024. PMID: 38920306. doi:10.14309/ajg.0000000000002915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。